[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513364":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":87,"collaborators":89,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":10,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":10,"enrollmentInfo":102,"targetDuration":105,"studyType":106,"phases":10,"briefSummary":107,"conditions":108,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Initial Cohort",null,"Up to 12 participants at each evaluation timepoint (approximately every 3-6 months to follow standard of care visits) will have up to 40 mL of blood drawn and distributed into 8 cell-free DNA Streck tubes, for plasma isolation, cell free DNA extraction, and ctDNA analysis. Blood for ctDNA analysis will be collected within +\u002F- 14 days of whole body imaging studies which will occur when patients are scheduled for standard of care whole body imaging.",[13],"Procedure: Blood Specimen",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Blood Specimen","Blood will be drawn via venipuncture",[9],[21],{"name":22,"affiliation":5,"role":23},"Rita Mukhtar, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Venezia Garza","CONTACT","415-353-8732","venezia.garza@ucsf.edu",[31,48,61,74],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"University of California, San Diego","RECRUITING","San Diego","California","92053","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-117.16472,32.71571,{"lat":43,"lon":42},[46],{"name":47,"role":23,"phone":10,"phoneExt":10,"email":10},"Rebecca Shatsky, MD",{"facility":5,"status":33,"city":49,"state":35,"zip":50,"country":37,"countryCode":38,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"San Francisco","94122",{"type":40,"coordinates":52},[53,54],-122.41942,37.77493,{"lat":54,"lon":53},[57,58,59],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"name":60,"role":23,"phone":10,"phoneExt":10,"email":10},"A. Jo Chien, MD",{"facility":62,"status":33,"city":63,"state":64,"zip":65,"country":37,"countryCode":38,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Abramson Cancer Center","Philadelphia","Pennsylvania","19104",{"type":40,"coordinates":67},[68,69],-75.16362,39.95238,{"lat":69,"lon":68},[72],{"name":73,"role":23,"phone":10,"phoneExt":10,"email":10},"Rachel Jankowitz, MD",{"facility":75,"status":33,"city":76,"state":77,"zip":78,"country":37,"countryCode":38,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":40,"coordinates":80},[81,82],-95.36327,29.76328,{"lat":82,"lon":81},[85],{"name":86,"role":23,"phone":10,"phoneExt":10,"email":10},"Jason Mouabbi, MD",{"type":88,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[90],{"name":91,"class":92},"METAvivor Research and Support, Inc","UNKNOWN","100513364","improving-survival-for-metastatic-lobular-breast-cancer-plumb-registry-100513364",false,"NCT05964504","Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)","Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer","Inclusion Criteria:\n\n1. Histologically confirmed invasive lobular carcinoma. Mixed lobular\u002Fductal cancer is allowed.\n2. Age \\>=18 years\n3. Any receptor subtype.\n4. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Stage I-III breast cancer.\n2. Lack of lobular histology on tumor biopsy.\n3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).","ALL","18 Years",{"count":103,"type":104},12,"ESTIMATED","10 Years","OBSERVATIONAL","This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.",[109,110],"Metastatic Breast Cancer","Lobular Breast Carcinoma","2026-06-30",{"date":113,"type":114},"2026-07-02","ACTUAL",{"date":116,"type":114},"2023-12-20",{"date":118,"type":104},"2036-02-28",{"name":5,"class":6},4]